-

IFF’s Designed Enzymatic Biomaterials™ Platform Sees First Large-Scale Use in Home Care Applications

Designed Enzymatic Biomaterials™ (DEB) platform debuts in laundry formulations with major consumer packaged goods launch

NEW YORK--(BUSINESS WIRE)--IFF (NYSE: IFF) — a global leader in flavors, fragrances, food ingredients, health and biosciences — announced the first large-scale commercial use of its Designed Enzymatic Biomaterials™ (DEB) platform, as a major consumer packaged goods (CPG) company has launched a new laundry detergent formulation enhanced by DEB technology. The formulation delivers improved fabric softness and cleaning performance while replacing non-biodegradable ingredients with a readily biodegradable alternative.

“DEB has the power to redefine how (bio)chemical materials will look in the 21st century: tailored, functional, nature-inspired and safer,” said Leticia Gonçalves, president of Health & Biosciences at IFF. “It brings together biotechnology, molecular design and sustainability to deliver solutions that were unimaginable just a few years ago. This launch is just the beginning — DEB’s potential reaches far beyond any single category, and we’re exploring what sustainability and performance benefits it can unlock across different industries.”

Developed by IFF’s Health & Biosciences business unit, the DEB platform leverages advanced bioscience to create unique and structurally diverse polysaccharides like those found in nature, but at scale, with accuracy and consistency typically only found in traditional industrial polymers. Engineered from renewable plant sugar sources, these biomaterials are customized to enable tailored functionality and deliver specific performance attributes across applications. In laundry formulations, the Lyrature™ portfolio with DEB-based products will replace persistent, non-biodegradable ingredients such as polyquaterniums, offering a bio-based solution that enhances surface modification and supports anti-redeposition benefits.

IFF is further scaling DEB through its joint venture with Kemira, Alpha Bio, which will house a first-of-its-kind manufacturing asset dedicated to DEB-based materials. Following extensive process and product validation at the Kokemäki and Jokioinen plants in Finland, AlphaBio is working with a growing network of customers and partners to bring DEB-based solutions from this facility to multiple market sectors starting in 2027. As the platform evolves, IFF is focused on unlocking its full potential, delivering products that meet the demands of modern performance while advancing a more sustainable future across industries, including health, nutrition, beauty, packaging, and more.

To learn more about the DEB platform, visit: IFF | Designed Enzymatic Biomaterials™ (DEB)

Cautionary Statement under the Private Securities Litigation Reform Act of 1995

This press release contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as “”plan”, “expect,” “anticipate,” “intend,” “believe,” “seek,” “see,” “will,” “would,” “target,” similar expressions, and variations or negatives of these words. Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about the timing or nature of future product launches, and commercial partnerships. The forward-looking statements included in this release are made only as of the date hereof, and we undertake no obligation to update the forward-looking statement to reflect subsequent events or circumstances.

Welcome to IFF

At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products — advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.com, LinkedIn, Instagram and Facebook.

©2025 International Flavors & Fragrances Inc. (IFF). IFF, the IFF Logo, and all trademarks and service marks denoted with ™, SM or ® are owned by IFF or affiliates of IFF unless otherwise noted. All Rights Reserved. 

Contacts

Media Relations:
Paulina Heinkel
332.877.5339
Media.request@iff.com

Investor Relations:
Michael Bender
212.708.7263

IFF IFF

NYSE:IFF


Contacts

Media Relations:
Paulina Heinkel
332.877.5339
Media.request@iff.com

Investor Relations:
Michael Bender
212.708.7263

More News From IFF IFF

IFF Introduces Smart Dosing Robot to Transform Fragrance Production

CHIN BEE, Singapore--(BUSINESS WIRE)--IFF (NYSE: IFF) — a global leader in flavors, fragrances, food ingredients, health and biosciences, has implemented the Colibri robot in its Chin Bee production facility. This advanced industrial dosing system can produce fragrance sample batches on demand in minutes, reimagining and expediting the fragrance development journey for local, regional and global customers in Greater Asia. The new robotic system, installed at the company's cross-category Scent a...

IFF Benicarló Pioneers On-Site Green Hydrogen Production Facility for Sustainable Fragrance Ingredient Manufacturing

BENICARLÓ, Spain--(BUSINESS WIRE)--IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients and biosciences, announced the installation of a nature-based hydrogen production facility at its Scent R&D and fragrance ingredients manufacturing plant in Benicarló, Spain. The site has partnered with Iberdrola, one of the world’s largest producers of renewable energy, to become the first in the fragrance industry to rely on renewable electricity for hydrogenation reactions used in...

IFF Reports Third Quarter 2025 Results

NEW YORK--(BUSINESS WIRE)--IFF (NYSE: IFF) reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Consolidated Summary: Reported (GAAP)   Adjusted (Non-GAAP)1 Sales   Income Before Taxes   EPS   Operating EBITDA   Operating EBITDA Margin   EPS ex Amortization $2.7 B   $56 M   $0.16   $519 M   19.3%   $1.05 First Nine Months 2025 Consolidated Summary: Reported (GAAP)   Adjusted (Non-GAAP)1 Sales   Income Before Taxes   EPS   Operating EBITDA   Operating EBI...
Back to Newsroom